MehdiMMoeziMDFACP

Oncology • Fleming Island, FL

Breast Cancer, Gastrointestinal Cancer, Hematologic Oncology, Thoracic Cancer

Cancer Specialists of North Florida

Join to view full profile

Dr. Moezi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Moezi's full profile

Already have an account?

Office
2370 Marker Drive
Fleming Island, FL 32003
Phone+1 904-264-6201

Fax+1 904-264-6858
Is this information wrong?

Education & Training

SUNY Downstate Health Sciences UniversityFellowship, Hematology and Medical Oncology, 1998 - 2001
One Brooklyn Health System/Interfaith Medical CenterResidency, Internal Medicine, 1995 - 1998
Tehran University of Medical Sciences School of MedicineClass of 1990

Certifications & Licensure

CA State Medical License 2005 - Present
FL State Medical License 2000 - 2026
UT State Medical License 1998 - 2006
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2012-2013

Clinical Trials

Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts Start of enrollment: 2010 Nov 01
Completed
Phase 3
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant Start of enrollment: 2011 Apr 20
Completed
Phase 3
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma Start of enrollment: 2011 Aug 04
Completed
Phase 3
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma Start of enrollment: 2011 Nov 30
Completed
Phase 2
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 02
Terminated
Phase 3
Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2014 Feb 05
Terminated
Phase 3
Join now to see all

Publications & Presentations

PubMed

4 citations
Ruxolitinib and methylprednisolone for treatment of patients with relapsed/refractory multiple myeloma.
James R Berenson, Daisy Martinez, Tahmineh Safaie, Ralph Boccia, Honghao Yang, Mehdi Moezi, Stephen Lim, Gary Schwartz, Shahrooz Eshaghian, Regina Swift, Benjamin M Ea...> ;British Journal of Haematology. 2023 Mar 1
2 citations
A real-world study to evaluate the safety and efficacy of three injectable neurokinin-1 receptor antagonist formulations for the prevention of chemotherapy-induced nau...
George Dranitsaris, Mehdi Moezi, Kate Dobson, Robert Phelan, Sibel Blau> ;Supportive Care in Cancer. 2022 Aug 1
1 citations
A phase 1/2 study of ixazomib in place of bortezomib or carfilzomib in a subsequent line of therapy for patients with multiple myeloma refractory to their last bortezo...
David Daniely, Eli Forouzan, Tanya M Spektor, Alexa Cohen, Jacob D Bitran, Gigi Chen, Mehdi M Moezi, Alberto Bessudo, John Hrom, Shahrooz Eshaghian, Regina A Swift, Be...> ;Experimental Hematology. 2022 Jul 1
2 citations
Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment.
Aleksandra Vidisheva, James Wang, Tanya M. Spektor, Jacob D. Bitran, Jose Lutzky, Imad A. Tabbara, Joseph Z. Ye, Sikander Ailawadhi, Laura Stampleman, Ronald G. Steis,...> ;Supportive Care in Cancer. 2017 Apr 28
47 citations
Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer.
Corey J. Langer, Istvan Albert, Helen J. Ross, Peter Kovacs, L. Johnetta Blakely, Gabor Pajkos, Attila Somfay, Petr Zatloukal, Andrzej Kazarnowicz, Mehdi M. Moezi, Mar...> ;Lung Cancer. 2014 Sep 1
A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-sta...
Chiappori, A. A., Schreeder, M. T., Moezi, M. M., Stephenson, J. J., Blakely, J., Salgia, R., Chu, Q. S., Ross, H. J., Subramaniam, D. S., Schnyder, J., Berger, M. S.> ;Br J Cancer. 2012 Feb 28
A randomized phase II study of carboplatin (C) and etoposide (E) with or without pan-BCL-2 antagonist obatoclax (Ob) in extensive-stage small cell lung cancer (ES-SCLC).
Langer CJ, Albert I, Kovacs P, Blakely LJ, Pajkos G, Petrov P, Somfay A, Szczesna A, Zatloukal P, Kazarnowicz A, Moezi MM, Schreeder MT, Schnyder J, Berger MS> ;J. Clin. Oncol.. 2011-05-20
49 citations
Zoledronic Acid Markedly Improves Bone Mineral Density for Patients with Monoclonal Gammopathy of Undetermined Significance and Bone Loss
James R. Berenson, Ori Yellin, Ralph V. Boccia, Marshall S. Flam, Siu Fun Wong, Olcay Batuman, Mehdi M. Moezi, Donald Woytowitz, Herbert Duvivier, Youram Nassir, Regin...> ;Clinical Cancer Research. 2008 Oct 1
Marked improvement in bone mineral density (BMD) for patients (pts) with monoclonal gammopathy of undetermined significance (MGUS) using zoledronic acid (ZOL).
Berenson JR, Yellin O, Boccia RV, Flam MS, Wong S, Batuman O, Moezi MM, Woytowitz DV, Duvivier HL, Nassir Y, Swift R> ;J. Clin. Oncol.. 2008-05-20
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
American Society of Hematology - ASH
Member
American College of Physicians - ACP
Member
American Medical Association - AMA
Member
European Society of Medical Oncology
Member

Other Languages

Farsi

Hospital Affiliations

HCA Florida Orange Park HospitalOrange Park, Florida
Baptist Medical Center JacksonvilleJacksonville, Florida